Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota

CRS3123 is a novel small molecule that potently inhibits methionyl-tRNA synthetase of Clostridioides difficile, inhibiting C. difficile toxin production and spore formation. CRS3123 has been evaluated in a multiple-ascending-dose placebo-controlled phase 1 trial. Thirty healthy subjects, ages 18 to...

Descripción completa

Detalles Bibliográficos
Autores principales: Lomeli, Barbara K., Galbraith, Hal, Schettler, Jared, Saviolakis, George A., El-Amin, Wael, Osborn, Blaire, Ravel, Jacques, Hazleton, Keith, Lozupone, Catherine A., Evans, Ronald J., Bell, Stacie J., Ochsner, Urs A., Jarvis, Thale C., Baqar, Shahida, Janjic, Nebojsa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2019
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187627/
https://www.ncbi.nlm.nih.gov/pubmed/31685472
http://dx.doi.org/10.1128/AAC.01395-19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187627/
https://www.ncbi.nlm.nih.gov/pubmed/31685472
http://dx.doi.org/10.1128/AAC.01395-19

Ejemplares similares